Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases

Funding Organization: 
Type of Funding: 
Estimated Funding Amount: 
Up to $250K per year
Funding Announcement: 
Proposal Deadline: 
Tuesday, April 9, 2019
Award/Eligibility Description: 

The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice.  This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms.  This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.


The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This R61/R33 application and the companion X02 pre-application (PAR-19-XXX ) encourage applications related to musculoskeletal diseases.

The X02 is the highly recommended (not required) first step in the application process for this FOA. Potential applicants should read both FOAs.  

Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program, will be notified of the opportunity to submit an R61/R33 application to this FOA.

The R61/R33 is a two-phase application.

The R61 Phase will provide up to two years of support to perform critical experiments that rigorously test the proposed concept.  These critical experiments should unambiguously support or reject the central hypothesis.  The outcomes of these critical experiments will be the main determining factor for the activation of the R33 Phase, which will provide up to one additional year of support to further validate and explore the innovative concept.